Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (SBIR [R43/44])

Jurisdiction:
Federal
Incentive Type:Grant Program
Industries:
Medical, Education, Health And Safety
Eligible Sector:
Business
Category:
Financial Incentive
Time Period:
FY 2015
Governing Body:National Institutes of Health
What’s it worth?:Not mentioned

The Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care program encourages research for commercial development of new cancer-relevant technologies. These research projects are expected to further develop highly-innovative technologies used to overcome challenges of cancer research or clinical care. Technological areas of interest include but are not excluded to:

  • Technology capable of converting basic mechanisms underlying cancer initiation and progression.
  • Technology to improve early cancer detection and/or cancer risk assessment
  • Technology to distinguish, assess, and/or monitor cancer progression
  • Technology to assist in the drug discovery or development
  • Technology to enhance molecular analyses in cancer epidemiology
  • Technology for sample preparation and processing
  • Technology that provides a new means for general analyte quality assessment
  • Technology or tools that help penetrate research barriers on the incidence, prevalence, mortality, and burden of cancer among members of undeserved populations

Typical award amounts of not more than $225,000 for Phase I projects and up to $1,500,000 for Phase II projects with project duration of up to two years. All applicants must meet the following criteria.